Advertisement

Advertisement

CLRB Stock Latest News

Cellectar Biosciences Earnings Call Highlights Clinical Momentum

Company AnnouncementsCellectar Biosciences Earnings Call Highlights Clinical Momentum

Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)

PremiumThe Fly

Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)

1M ago

Cellectar: Solid Cash Runway and De-Risking Clinical Milestones Support Buy Rating; $10 Price Target Reiterated

PremiumRatings

Cellectar: Solid Cash Runway and De-Risking Clinical Milestones Support Buy Rating; $10 Price Target Reiterated

1M ago

Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar

PremiumCompany Announcements

Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar

1M ago

Cellectar Biosciences Inc (CLRB) Q2 Earnings Cheat Sheet

PremiumPre-Earnings

Cellectar Biosciences Inc (CLRB) Q2 Earnings Cheat Sheet

2M ago

Cellectar Biosciences publishes iopofosine I 131 dose-escalation study results

PremiumThe FlyCellectar Biosciences publishes iopofosine I 131 dose-escalation study results

2M ago

Cellectar Biosciences initiated with a Buy at Brookline

The Fly

Cellectar Biosciences initiated with a Buy at Brookline

3M ago

Cellectar Biosciences Shareholders Approve Key Governance Measures

Company Announcements

Cellectar Biosciences Shareholders Approve Key Governance Measures

3M ago

Cellectar Biosciences Bets on Iopofosine Breakthrough

PremiumCompany Announcements

Cellectar Biosciences Bets on Iopofosine Breakthrough

4M ago

Cellectar Biosciences files to sell 51.21M shares of common stock for holders

PremiumThe Fly

Cellectar Biosciences files to sell 51.21M shares of common stock for holders

4M ago

Cellectar Biosciences Announces Board Changes and New Director

PremiumCompany Announcements

Cellectar Biosciences Announces Board Changes and New Director

4M ago

Cellectar Biosciences assumed with a Buy at Ladenburg

PremiumThe Fly

Cellectar Biosciences assumed with a Buy at Ladenburg

4M ago

Cellectar Biosciences Signals Pivotal Turn in Earnings Call

PremiumCompany AnnouncementsCellectar Biosciences Signals Pivotal Turn in Earnings Call

4M ago

Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)

The Fly

Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)

4M ago

CLRB Upcoming Earnings Report: What to Expect?

Pre-Earnings

CLRB Upcoming Earnings Report: What to Expect?

5M ago

Cellectar Raises $35M to Advance Phase 3 Trial

PremiumCompany Announcements

Cellectar Raises $35M to Advance Phase 3 Trial

5M ago

Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital

PremiumThe Fly

Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital

5M ago

Cellectar Biosciences reports CLOVER WaM trial achieves primary endpoint

PremiumThe Fly

Cellectar Biosciences reports CLOVER WaM trial achieves primary endpoint

5M ago

Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target

PremiumRatings

Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target

5M ago

Cellectar Biosciences enrolls first patient in CLR 121125 trial

PremiumThe FlyCellectar Biosciences enrolls first patient in CLR 121125 trial

5M ago

Cellectar Biosciences upgraded to Buy from Hold at Maxim

The Fly

Cellectar Biosciences upgraded to Buy from Hold at Maxim

7M ago

Cellectar Biosciences Charts Risky Path to Approvals

Company Announcements

Cellectar Biosciences Charts Risky Path to Approvals

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >